GH and LR3-IGF-I boost mouse lactation via distinct mammary signaling pathways
Background
Lactation insufficiency and the search for agents to enhance milk production are long-standing challenges in both agricultural and biomedical contexts. GH, prolactin (PRL), and IGF-I are known to stimulate lactation-related metabolic processes in mammary epithelial cells, yet their efficacy varies widely across species and experimental conditions. Prior transgenic work showed that overexpression of des(1-3)IGF-I within the mammary gland elevated lactation capacity during prolonged lactation, though some effects appeared systemic rather than local. A key unanswered question was whether exogenous peptide administration could replicate these benefits, and whether GH acts purely through IGF-I-dependent pathways or has independent mammary-level effects.
Study Design
Lactating mouse dams underwent prolonged lactation and received subcutaneous injections of murine GH, murine PRL, or the human IGF-I analog long-R3-IGF-I (LR3). Primary endpoint was lactation capacity, measured by litter weight gain (P<0.05 threshold). Mammary gland tissue was analyzed by qPCR for gene expression — including SOCS1, SOCS3, and tryptophan hydroxylase 1 (TPH1) — and by phosphoprotein assay for phospho-Akt levels. A control arm with no exogenous peptide treatment was used for comparison across all groups.
Results
GH significantly increased lactation capacity as measured by litter gain (P<0.05), while PRL failed to produce a statistically significant improvement. LR3 had a modest but significant (P<0.05) effect on lactation capacity. LR3 administration elevated mammary phospho-Akt (P<0.05), consistent with activation of the PI3K/Akt signaling pathway, and also increased SOCS3 gene expression (P<0.05). GH increased mammary SOCS1 expression (P<0.05) and, critically, decreased expression of tryptophan hydroxylase 1 (TPH1) — the rate-limiting enzyme in serotonin synthesis and a putative feedback inhibitor of lactation — (P<0.05).
GH both upregulated mammary
SOCS1and suppressedTPH1expression, implicating an IGF-I-independent mechanism through repression of mammary serotonin synthesis.
These divergent signaling profiles suggest that GH and IGF-I enhance milk production through at least partially non-overlapping intracellular pathways within the mammary epithelium.
Key Findings
- GH increased lactation capacity (litter gain, P<0.05); PRL did not reach significance.
- LR3 modestly but significantly increased lactation capacity (P<0.05) and elevated mammary phospho-Akt (P<0.05).
- LR3 increased mammary SOCS3 gene expression (P<0.05).
- GH increased mammary SOCS1 expression (P<0.05) and decreased TPH1 expression (P<0.05).
- GH's lactation-enhancing effect is linked to IGF-I-independent suppression of mammary serotonin synthesis.
Why It Matters
GH's ability to suppress mammary TPH1 and thereby reduce local serotonin synthesis adds a mechanistic layer that is entirely separate from the classical GH → IGF-I axis, meaning that stacking GH with LR3 could engage complementary pathways rather than redundant ones. For clinicians or researchers exploring lactation support protocols, the failure of exogenous PRL to enhance litter gain — despite its central role in lactation biology — signals that simply elevating circulating PRL is unlikely to be the rate-limiting strategy. The identification of SOCS3 as an LR3-responsive gene and SOCS1 as a GH-responsive gene raises questions about cytokine-feedback crosstalk that could limit sustained dosing efficacy. Translation to humans remains distant, as all data are from mice and rely on prolonged lactation models that may not reflect typical human postpartum physiology.
